JGJean Gariépy

Jean Gariépy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean Gariépy has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Aaron Prodeus

    Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

    9 shared publications
  • Marzena Cydzik

    Physical Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada

    7 shared publications
  • Nicholas William Fischer

    Program in Genetics and Genome Biology, The Hospital for Sick Children; Toronto, Ontario, Canada

    6 shared publications
  • Aws Abdul-Wahid

    Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics and Pharmaceutical Sciences, Department of Cell & Systems Biology, Department of Immunology, and Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada

    5 shared publications
  • Amirul Islam Mallick

    Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 2M9, Canada

    2 shared publications
  • Aws Abdul‐Wahid

    Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada

    2 shared publications

Latest Publications

  • Open Access

    A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo

    by Aaron Prodeus, Amanda Sparkes, Nicholas W. Fischer, Marzena Cydzik, Eric Huang, Ismat Khatri, Ashley Young, Lindsay Woo, Chung Wai Chow, Reginald Gorczynski, et al.


  • Open Access

    Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity

    by Nicholas W. Fischer, Aaron Prodeus, Jean Gariépy

    BACKGROUND. There is currently no clinical distinction between different TP53 mutations, despite increasing evidence that not all mutations have equally deleterious effects on the activity of the encoded tumor suppressor protein p53. The objective of this study was to determine whether these biological differences have clinical significance. METHODS. This retrospective cohort analysis included 2,074 patients with sporadic TP53 mutations (403 unique mutations) and 1,049 germline TP53 mutation carriers (188 unique mutations). Survival was projected by stratifying patients according to their p53 mutant–specific residual transcriptional activity scores. RESULTS. Pan-cancer survival analyses revealed a strong association between increased mutant p53 residual activity and improved survival in males with glioma and gastric adenocarcinoma ( P = 0.002 and P = 0.02) that was not present in the female cohorts ( P = 0.16 and P = 0.50). Male glioma and gastric cancer patients with TP53 mutations resulting in >5% transcriptional activity had 3.1-fold (95% CI, 2.4–3.8; P = 0.002; multivariate analysis hazard ratio [HR]) and 4.6-fold (95% CI, 3.7–5.6; P = 0.001; multivariate analysis HR) lower risk of death as compared with patients harboring inactive (0% activity) p53 mutants. The correlation between mutant p53 residual activity with survival was recapitulated in the dataset of germline TP53 mutation carriers (HR = 3.0, 95% CI, 2.7–3.4, P < 0.001 [females]; HR = 2.2, 95% CI, 1.8–2.6, P < 0.001 [males]), where brain and gastric tumors were more common among males ( P < 0.001 and P = 0.001, respectively). CONCLUSION. The retention of mutant p53 transcriptional activity prognosticates superior survival for men with glioma and gastric adenocarcinoma harboring sporadic TP53 mutations. Among germline TP53 mutation carriers, increased residual transcriptional activity is correlated with prolonged lifetime cancer survival and delayed tumor onset, and males are more prone to develop brain and gastric tumors. FUNDING. Canadian Institutes of Health Research (no. 148556).


  • Open Access

    Serum‐derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re‐modeling of the extracellular matrix that favors the engraftment of CEA‐expressing tumor cells

    by Aws Abdul‐Wahid, Marzena Cydzik, Nicholas W. Fischer, Aaron Prodeus, John E Shively, Anne Martel, Samira Alminawi, Zeina Ghorab, Neil L. Berinstein, Jean Gariépy

    Elevated levels of the carcinoembryonic antigen (CEA; CEACAM5) in the serum of colorectal cancer (CRC) patients represent a clinical biomarker that correlates with disease recurrence. However, a mechanistic role for soluble CEA (sCEA) in tumor progression and metastasis remains to be established. In our study, we report that sCEA acts as a paracrine factor, activating human fibroblasts by signaling through both the STAT3 and AKT1‐mTORC1 pathways, promoting their transition to a cancer‐associated fibroblast (CaF) phenotype. sCEA‐activated fibroblasts express and secrete higher levels of fibronectin, including cellular EDA+‐fibronectin (Fn‐EDA) that selectively promote the implantation and adherence of CEA‐expressing cancer cells. Immunohistochemical analyses of liver tissues derived from CRC patients with elevated levels of sCEA reveal that the expression of cellular Fn‐EDA co‐registers with CEA‐expressing liver metastases. Taken together, these findings indicate a direct role for sCEA as a human fibroblast activation factor, in priming target tissues for the engraftment of CEA‐expressing cancer cells, through the differentiation of tissue‐resident fibroblasts, resulting in a local change in composition of the extracellular matrix.


  • Open Access

    VISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses

    by Aaron Prodeus, Aws Abdul-Wahid, Amanda Sparkes, Nicholas W. Fischer, Marzena Cydzik, Nicholas Chiang, Mays Alwash, Alessandra Ferzoco, Nathalie Vacaresse, Michael Julius, et al.

    V-domain immunoglobulin suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint ligand that functions to suppress T cell activity. The therapeutic potential of activating this immune checkpoint pathway to reduce inflammatory responses remains untapped, largely due to the inability to derive agonists targeting its unknown receptor. A dimeric construct of the IgV domain of VISTA (VISTA-Fc) was shown to suppress the activation of T cells in vitro. However, this effect required its immobilization on a solid surface, suggesting that VISTA-Fc may display limited efficacy as a VISTA-receptor agonist in vivo. Herein, we have designed a stable pentameric VISTA construct (VISTA.COMP) by genetically fusing its IgV domain to the pentamerization domain from the cartilage oligomeric matrix protein (COMP). In contrast to VISTA-Fc, VISTA.COMP does not require immobilization to inhibit the proliferation of CD4 + T cells undergoing polyclonal activation. Furthermore, we show that VISTA.COMP, but not VISTA-Fc, functions as an immunosuppressive agonist in vivo capable of prolonging the survival of skin allografts in a mouse transplant model as well as rescuing mice from acute concanavalin-A–induced hepatitis. Collectively, we believe our data demonstrate that VISTA.COMP is a checkpoint receptor agonist and the first agent to our knowledge targeting the putative VISTA-receptor to suppress T cell–mediated immune responses.


  • p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis

    by Nicholas W. Fischer, Aaron Prodeus, David Malkin, Jean Gariépy

    Mutations in the oligomerization domain of p53 are genetically linked to cancer susceptibility in Li-Fraumeni Syndrome. These mutations typically alter the oligomeric state of p53 and impair its transcriptional activity. Activation of p53 through tetramerization is required for its tumor suppressive function by inducing transcriptional programs that lead to cell fate decisions such as cell cycle arrest or apoptosis. How p53 chooses between these cell fate outcomes remains unclear. Here, we use 5 oligomeric variants of p53, including 2 novel p53 constructs, that yield either monomeric, dimeric or tetrameric forms of p53 and demonstrate that they induce distinct cellular activities and gene expression profiles that lead to different cell fate outcomes. We report that dimeric p53 variants are cytostatic and can arrest cell growth, but lack the ability to trigger apoptosis in p53-null cells. In contrast, p53 tetramers induce rapid apoptosis and cell growth arrest, while a monomeric variant is functionally inactive, supporting cell growth. In particular, the expression of pro-arrest CDKN1A and pro-apoptotic P53AIP1 genes are important cell fate determinants that are differentially regulated by the oligomeric state of p53. This study suggests that the most abundant oligomeric species of p53 present in resting cells, namely p53 dimers, neither promote cell growth or cell death and that shifting the oligomeric state equilibrium of p53 in cells toward monomers or tetramers is a key parameter in p53-based cell fate decisions.


  • Induction of antigen‐specific TH9 immunity accompanied by mast cell activation blocks tumor cell engraftment

    by Aws Abdul‐Wahid, Marzena Cydzik, Aaron Prodeus, Mays Alwash, Mile Stanojcic, Megan Thompson, Eric H.‐B. Huang, John E. Shively, Scott D. Gray‐Owen, Jean Gariépy

    The engraftment of circulating cancer cells at distal sites represents a key step in the metastatic cascade, yet remains an unexplored target for therapeutic intervention. In this study, we establish that a vaccination strategy yielding an antigen‐specific TH9 response induces long term host surveillance and prevents the engraftment of circulating cancer cells. Specifically, we show that vaccination with a recombinant CEA IgV‐like N domain, formulated with the TLR3 ligand poly I:C, elicits a CEA‐specific TH9 response, wherein IL‐9 secreting TH cells act in concert with CEA N domain‐specific antibodies as well as activated mast cells in preventing tumor cell engraftment. The development of this immune response was dependent on TLR3, since interference with the TLR3‐dsRNA complex formation led to a reduction in vaccine‐imparted protection and a shift in the resulting immune response toward a TH2 response. These findings point to the existence of an alternate tumor targeting immune mechanism that can be exploited for the purpose of developing vaccine therapies targeting tumor dissemination and engraftment.


  • Open Access

    Slow binding kinetics of secreted protein, acidic, rich in cysteine-VEGF interaction limit VEGF activation of VEGF receptor 2 and attenuate angiogenesis

    by Marzena Cydzik, Aws Abdul-Wahid, Soyeon Park, Annie Bourdeau, Katherine Bowden, Aaron Prodeus, Alexandra Kollara, Theodore J. Brown, Maurice J. Ringuette, Jean Gariépy

    VEGF-A (VEGF) drives angiogenesis through activation of downstream effectors to promote endothelial cell proliferation and migration. Although VEGF binds both VEGF receptor 1 (R1) and receptor 2 (R2)...


  • Open Access

    Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers

    by Aaron Prodeus, Aws Abdul-Wahid, Nicholas W Fischer, Eric H-B Huang, Marzena Cydzik, Jean Gariépy


  • Open Access

    Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival

    by Aaron Prodeus, Marzena Cydzik, Aws Abdul-Wahid, Eric Huang, Ismat Khatri, Reginald Gorczynski, Jean Gariépy


  • Open Access

    The carcinoembryonic antigen IgV‐like N domain plays a critical role in the implantation of metastatic tumor cells

    by Aws Abdul-Wahid, Eric H.-B. Huang, Marzena Cydzik, Eleonora Bolewska-Pedyczak, Jean Gariépy

    The human carcinoembryonic antigen (CEA) is a cell adhesion molecule involved in both homotypic and heterotypic interactions. The aberrant overexpression of CEA on adenocarcinoma cells correlates with their increased metastatic potential. Yet, the mechanism(s) by which its adhesive properties can lead to the implantation of circulating tumor cells and expansion of metastatic foci remains to be established. In this study, we demonstrate that the IgV‐like N terminal domain of CEA directly participates in the implantation of cancer cells through its homotypic and heterotypic binding properties. Specifically, we determined that the recombinant N terminal domain of CEA directly binds to fibronectin (Fn) with a dissociation constant in the nanomolar range (KD 16 ± 3 nM) and interacts with itself (KD 100 ± 17 nM) and more tightly to the IgC‐like A3 domain (KD 18 ± 3 nM). Disruption of these molecular associations through the addition of antibodies specific to the CEA N or A3B3 domains, or by adding soluble recombinant forms of the CEA N, A3 or A3B3 domains or a peptide corresponding to residues 108–115 of CEA resulted in the inhibition of CEA‐mediated intercellular aggregation and adherence events in vitro. Finally, pretreating CEA‐expressing murine colonic carcinoma cells (MC38.CEA) with rCEA N, A3 or A3B3 modules blocked their implantation and the establishment of tumor foci in vivo. Together, these results suggest a new mechanistic insight into how the CEA IgV‐like N domain participates in cellular events that can have a macroscopic impact in terms of cancer progression and metastasis.